# Publications

1.	Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar B, Chen L, Braganza C, Montgomery C, Mendell JR. AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy. Molecular Therapy 2014: Mar;22(3):511-521.

2.	Chicoine LG, Montgomery CL, Bremer WG, Shontz KM, Griffin DA, Heller KN, Lewis S, Malik V, Shilling CJ, Campbell KJ, Preston TJ, Coley BD, Martin PT, Walker CM, Clark KR, Sahenk Z, Mendell JR, and Rodino-Klapac LR. Path forward to vascular delivery for DMD: Plasmapheresis eliminates the negative impact of AAV antibodies on therapeutic gene expression. Molecular Therapy 2014: 22(2):338-347.

3.	Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Kean JR, Allen HD, Shilling CJ, Sazani P, Saoud JB, Laye EM, Melia KR. (2013)  Eteplirsen Restores Dystrophin and Stabilizes Walking Ability in Patients with Duchenne’s Muscular Dystrophy. Ann Neurol. 2013 Nov;74(5):637-647. 
 
4.	Rosales XQ, Malik V, Sneh  A, Chen L, Lewis S, Kota J, Gastier-Foster JM, Astbury C, Pyatt R, Reshmi S, Rodino-Klapac LR, Clark KR, Mendell JR, Sahenk Z. (2012). Impaired regeneration in LGMD2A supported by increased Pax7 positive satellite cell content and muscle specific microRNA dysregulation. Muscle Nerve. 2013 May;47(5):731-9

5.	Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, Montgomery CL, Lewis S, Brown RH Jr, Janssen PM, Mendell JR, Rodino-Klapac LR (2012). Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One. 7(6):e39233. Epub 2012 Jun 15.

6.	Malik V, Rodino-Klapac LR, Mendell JR (2012) Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs.17(2):261-77

7.	Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark KR. 2012 Gene therapy for muscular dystrophy: Lessons learned and path forward. Neurosci Lett.  11;527(2):90-9.

8.	Malik V, Rodino-Klapac LR, Viollet L, Mendell JR. (2010). Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord. 2010 Nov;3(6):379-89

9.	Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR. (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol. 2010 Nov;68(5):629-38.

10.	Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ, Walker CM. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010 Oct 7;363(15):1429-37.

11.	Sahenk Z, Galloway G, Edwards C, Malik V, Kaspar BK, Eagle A, Yetter B, Forgie A, Tsao D, Lin JC. (2010) TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice. Exp Neurol. 2010 Aug;224(2):495-506

12.	Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Serrano-Munuera C, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM, Mendell JR. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.  Ann Neurol. 67(6):771-80.

13.	Rodino-Klapac LR, Montgomery CL, Bremer WG, Shontz KM, Malik V, Davis N, Sprinkle S, Campbell KJ, Sahenk Z, Clark KR, Walker CM, Mendell JR and Chicoine LG (2010) Persistent expression of FLAG-tagged micro-dystrophin in nonhuman primates following intramuscular and vascular delivery. Molecular Therapy. 18:109-117.

14.	Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, Craenen JM, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Viollet L, Walker CM, Sahenk Z and Clark KR (2009) Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol. 66:290-1977.

15.	Rosales XQ, Gastier-Foster JM, Lewis S, Vinod M, Thrush DL, Astbury C, Pyatt R, Reshmi S, Sahenk Z, Mendell JR. (2010) Novel diagnostic features of dysferlinopathies. Muscle Nerve. 42(1):14-21.

16.	Mendell JR, Rodino-Klapac LR, Malik V (2010) Molecular therapeutic strategies targeting Duchenne muscular dystrophy. J Child Neurol. 2010 Sep;25(9):1145-8.

17.	Heine* G, Malik* V, Dias* AP and Grotewold E (2007) Expression and molecular characterization of ZmMYB-IF35 and related R2R3-MYB transcription factors. Molecular Biotechnology, 37:155-164.  *Authors contributed equally 

18.	Malik V. and Wu R. (2005) Regulated over-expression of a transcription factor, AtMYB2 from Arabidopsis confers salt and water-deficit tolerance in rice. Rice Genetics Newsletter, 22: 59-62.


Conference Presentations

•	Malik V, Shontz K, Montgomery CL, Lewis S, Sahenk Z, Clark KR, Rodino-Klapac LR, Mendell JR (2013). Dual Vector Mini-dystrophin delivery to include nNOSμ & C-terminal domains. Presented at American  Academy of Neurology, San Diego, March 2013.

•	Malik V, Willmann R, Straub V, Hesterlee S, Rafael-Fortney JA, Flanigan KM (2012). Analysis of pre-clinical studies of FDA approved drugs in the mdx mouse model of DMD. Presented at New Directions in Biology & Disease of Skeletal Muscle Conference, New Orleans, Louisiana , June 2012

•	William E. Grose, Danielle Griffin, Kim Shontz, Vinod Malik, Chrystal L. Montgomery, Paul M.L. Janssen, K. Reed Clark, Jerry R. Mendell, Louise R. Rodino-Klapac. Correction of Membrane Repair Defects in Dysferlin Deficient Muscle following AAV5 gene transfer. American Academy of Neurology, New Orleans, LA, April 2012

•	Boualoy T, Malik V, Lewis S, Mendell JR. (2011). Mini-dystrophin Dual Vector Cloning for Pre-clinical Studies in MDX Mice and Diagnostic Tools for DMD. Presented at Research Day at Nationwide Children’s Hospital  August 2011

•	William E. Grose, Danielle Griffin, Kim Shontz, Vinod Malik, Chrystal L. Montgomery, Paul M.L. Janssen, K. Reed Clark, Jerry R. Mendell, Louise R. Rodino-Klapac (2011). rAAV5 Mediated Delivery of Dysferlin as a Therapeutic Strategy for LGMD2B and Miyoshi Myopathy. Presented at OSU-NCH Muscle Group Trainee Poster Session 

•	William E. Grose, Danielle Griffin, Kim Shontz, Vinod Malik, Chrystal L. Montgomery, Paul M.L. Janssen, K. Reed Clark, Jerry R. Mendell, Louise R. Rodino-Klapac (2011). Correction of Membrane Repair Defects in Dysferlin Deficient Muscle following AAV5 gene transfer. Presented at Wellstone Network Meeting 2011

•	Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM, Mendell JR, 2010. Gentamicin treatment of Duchenne muscular dystrophy reinforces the potential for mutation suppression therapy. American Academy of Neurology held in April 2010 in Toronto, Canada.

•	Mendell JR, Campbell K, Rodino LR, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li, C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, Mcphee S, Samulski R and Walker C 2010. Transient expression of a therapeutic dystrophin transgene in Duchenne Muscular Dystrophy revealed by T cell mediated immunity. American Academy of Neurology held in April 2010 in Toronto, Canada.

•	Rodino-Klapac LR, Shontz KM, Montgomery CL, Malik V, Davis N, Janssen PML, Clark KR, Brown Jr. RH, and Mendell JR, 2010. AAV5 mediated delivery of Dysferlin as a therapeutic strategy for LGMD2B and Miyoshi myopathy. American Academy of Neurology held in April 2010 in Toronto, Canada.

•	Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM, Mendell JR, 2010. Gentamicin treatment of Duchenne muscular dystrophy reinforces the potential for mutation suppression therapy. American Society for Gene and Cell Therapy held in  2010 in Washington DC.

•	Rodino-Klapac LR, Malik V, Montgomery CL, Shontz KM, Davis N, Canan B, Janssen PML, Clark KR, Brown Jr. RH and Mendell JR (2009). rAAV5 mediated delivery of dysferlin as a therapeutic strategy for LGMD2B and Miyoshi Myopathy. 12th Annual Meeting of the American Society of Gene Therapy, May 27-30, 2009 San Diego, California.

•	Rodino-Klapac LR, Montgomery CL, Bremer WG, Malik V, Shontz KM, Davis N, Sprinkle S, Campbell KJ, Sahenk Z, Clark KR, Walker CM, Chicoine LG, Mendell JR (2009) Persistent expression of FLAG tagged micro-Dystrophin in non-human primates with intramuscular and vascular delivery. 12th Annual Meeting of the American Society of Gene Therapy, May 27-30, 2009 San Diego, California.

•	Malik V, Kota J, Rodino-Klapac LR, Campbell K, Viollet L, Lewis S, Shilling C, King W, Wall C, Walker C and Mendell JR (2009) Mutation suppression in DMD patients: pre- and post- gentamicin treatment, Presented at “Many Minds, One Team” Research Day at The Research Institute at Nationwide Children’s Hospital, May 19th, 2009 Columbus, OH.

•	Malik V, Edwards C, Galloway G, Sahenk Z (2009). Trkc agonist antibody improves the neurofilament cytoskeleton in sciatic nerves of Trembler-J mice. Presented at “Many Minds, One Team” Research Day at The Research Institute at Nationwide Children’s Hospital, May 19th, 2009 Columbus, OH.


Grant reviewed
Reviewed grant for French Muscular Dystrophy Association AFM (2012)
Study of nonsense-mediated mRNA decay (NMD) inhibition using small molecules as molecular probes 

Active grants
Co-Investigator, Dual-vector mediated reconstitution of mini-dystrophin transgene and restoration of dystrophin function in mdx model of DMD                             $300,000.00
